| ADC | Antibody-drug conjugate |
| AMT | adsorptive-mediated transcytosis |
| BBB | Blood-brain barrier |
| BM | Brain metastases |
| BMBC | Brain metastases in breast cancer |
| CDK 4/6i | CDK 4/6 inhibitors |
| CNS | Central nervous system |
| CMT | carrier-mediated transport |
| ESMO | European Society for Medical Oncology |
| ER | Estrogen receptor |
| MBC | metastatic breast cancer |
| NAC | neoadjuvant chemotherapy |
| OS | overall survival |
| PR | progesterone receptor |
| PFS | progression free survival |
| RMT | receptor-mediated transport |
| SG | sacituzumab-govitecan |
| SERM | selective estrogen receptor modulators |
| TPC | therapy of physician’s choice |
| TNBC | triple negative breast cancer |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.